A Phase 1 single ascending dose study of ITI-1284 in healthy volunteers including elderly subjects > than 65 years of age
Latest Information Update: 02 Mar 2021
At a glance
- Drugs Lumateperone (Primary)
- Indications Behavioural disorders; Dementia; Depressive disorders
- Focus Adverse reactions
- 02 Mar 2021 New trial record
- 24 Feb 2021 Results presented in an Intra-Cellular Therapies Media Release.